1 enrolling by invitation. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow eplontersen: new trials by email Literature Review of eplontersen trials Research Report on eplontersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Eplontersen - Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | Phase 3 | Enrolling by invitation | Ionis Pharmaceuticals, Inc. | 1400 | 2022-11-30 | 2026-04-17 |
Amyloidosis (1)
Ionis Pharmaceuticals, Inc. (1)
Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Japan (1) · Poland (1)